Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
KRYSTAL 2
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
- NCT04330664 ↗
- Completed
- Mirati Therapeutics Inc.
- Focused
We haven't built an HCP commentary report on KRYSTAL 2 (adagrasib plus TNO155 in KRAS G12C-mutated advanced solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KRYSTAL 2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
- Interventions
- MRTX849; TNO155
- Arms
- Phase 1 Dose Exploration · Experimental
- Phase 1b Expansion · Experimental
- Phase 2 · Experimental
- Enrollment
- 86
- Primary outcomes
- Characterize the safety of MRTX849 and TNO155 in patients having advanced solid tumor malignancies with KRAS G12C mutation.
- Evaluate the pharmacokinetics of MRTX849 and TNO155
- Sponsor
- Mirati Therapeutics Inc. with Novartis
- Start
- Apr 7, 2020
- Primary completion
- Jul 29, 2022
- Results posted
- No
- Registry record
- NCT04330664 · updated Apr 4, 2025